Semaglutide Leading the Next Generation of Obesity and Chronic Disease Treatment: Latest Clinical Advances and High-Quality Research Support

Obesity is not only a high-risk factor for type 2 diabetes and cardiovascular diseases, but it is also closely associated with chronic conditions such as knee osteoarthritis, which can lead to pain, stiffness, and a decline in quality of life. Weight loss is the core strategy for symptom improvement, and Semaglutide, with its potent GLP-1 receptor agonist properties, has quickly become the star drug in obesity treatment. As of the third quarter of 2024, global sales of Semaglutide have exceeded $20 billion. According to Novo Nordisk’s financial report, revenue for the first three quarters reached 141.213 billion Danish Kroner (approximately $20.38 billion), including Ozempic at $12.48 billion with a year-on-year increase of 32%, Rybelsus at $2.36 billion with a year-on-year increase of 28%, and Wegovy at $5.53 billion with a year-on-year increase of 76%. These figures underscore the enormous potential of Semaglutide in the fields of obesity and metabolic diseases.

Fig 1. Q3 Sales Growth

Mechanism of Action of Semaglutide

Semaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the physiological functions of GLP-1 to regulate multiple metabolic processes. Studies have shown that it has a significant effect on reducing body weight, improving blood sugar control, and alleviating inflammatory diseases (such as knee osteoarthritis). Semaglutide exerts its core function by binding to the GLP-1 receptor, which includes regulating the satiety center to reduce appetite and weight, delaying gastric emptying, promoting insulin secretion while inhibiting glucagon secretion to lower blood sugar, and mitigating obesity-related chronic inflammatory responses through weight loss and metabolic improvement. Its clinical applications have already covered diseases such as obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD), and further expanded indications (such as knee osteoarthritis) are currently under exploration. To date, on a global scale, Novo Nordisk has been investigating 22 indications for Semaglutide, including NASH, Alzheimer’s disease, and cardiovascular diseases.

New Highlights in Clinical Research on Semaglutide

A recent study published in NEJM titled "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis" investigated the efficacy of a once-weekly Semaglutide injection (2.4 mg) in patients with obesity and knee osteoarthritis, with remarkable results.

■ Significant Weight Reduction: Over 68 weeks, patients in the Semaglutide group experienced an average weight loss of 13.7%, significantly outperforming the placebo group’s 3.2% reduction. The dynamic changes in body weight between the treatment and placebo groups clearly illustrate the weight loss effect of Semaglutide.

Fig 2. Weight Change Curve

■ Significant Pain Improvement: The pain score in the Semaglutide group decreased by 41.7 points, compared to a 27.5-point decrease in the placebo group. Changes in the WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) demonstrate the excellent performance of Semaglutide in relieving pain and improving patients’ quality of life.

Fig 3. WOMAC Score

Semaglutide’s Breakthrough and the Research Support from AbinScience

The clinical research and market performance of Semaglutide fully demonstrate its enormous potential in the treatment of obesity, metabolic diseases, and related chronic conditions. However, in-depth research into the GLP-1 pathway requires high-quality reagents to ensure the reliability and reproducibility of experimental data. AbinScience is committed to providing researchers with top-quality antibodies and reagent kits, including the Semaglutide Detection Kit, GLP-1 pathway-related protein and antibody products, as well as a versatile product line for ELISA and immunoblotting, thereby assisting scientists in achieving further breakthroughs in obesity and metabolic disease research.

With rigorous production processes and strict quality control, AbinScience’s products provide robust technical support to researchers worldwide. Whether in basic research or clinical translation, AbinScience stands by you, contributing to the advancement of cutting-edge health science research. ChooseAbinSciencenow to boost the success of your experiments!

Recommended Popular Products:

References:

[1] Bliddal, Henning et al. “Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.” The New England Journal of Medicine vol. 391,17 (2024): 1573-1583. doi:10.1056/NEJMoa2403664